MULTIPLE MYELOMA

This study aimed to see if a stem cell transplant from a donor could cure multiple myeloma after it returns following initial treatment. It compared this intensive, one-time procedure to ongoing conventional drug therapy. The trial was for patients whose cancer had relapsed and w…

This early-stage study tested a new oral drug, INCB000928, to see if it could safely treat anemia (low red blood cells) in people with myelodysplastic syndromes (MDS) or multiple myeloma. The main goals were to find a safe dose and see if the drug could reduce the need for blood …

This early-stage study aimed to find a safe dose and check for side effects of an experimental drug, modakafusp alfa, when given with other standard myeloma medications. It involved adults with multiple myeloma, including those newly treated and those whose cancer had returned. T…

This early-stage study tested a drug called tasquinimod, both by itself and combined with standard myeloma medications, in people whose multiple myeloma had returned or stopped responding to treatment. The main goals were to find the highest safe dose and to get a first look at w…

This study compared two different stem cell transplant approaches for people aged 60+ with multiple myeloma, a blood cancer. Researchers tested whether adding a drug called bortezomib to the standard transplant chemotherapy would help patients live longer without their cancer wor…

This study tested a new oral drug, CC-92480, given alone and with a steroid (dexamethasone), for adults with multiple myeloma that has come back and stopped responding to many standard treatments. The main goals were to find a safe dose and see if the drug combination could shrin…

This early-stage study tested the safety and initial effectiveness of a new drug, modakafusp alfa, when given alongside an existing drug, daratumumab, for people with multiple myeloma that has returned or stopped responding to other treatments. The main goal was to find a safe do…

This early-stage trial tested whether combining a personalized immune cell therapy (called bb2121 or ide-cel) with other drugs could help adults with multiple myeloma that had returned or stopped responding to standard treatments. The study aimed to find safe doses and see if the…

This early-phase study aimed to see if a drug called belantamab mafodotin (Blenrep) could help prevent multiple myeloma from returning in patients who had already relapsed and received a salvage stem cell transplant. Researchers wanted to test the safety of giving this drug as on…

This study tested an experimental cell therapy called PHE885 for adults with multiple myeloma that has returned or stopped responding to multiple standard treatments. Researchers collected immune cells from participants, genetically modified them to target cancer cells, and reinf…

This study tested a new drug called modakafusp alfa for people with multiple myeloma, a type of blood cancer, that had returned or stopped responding to at least three prior treatments. The main goals were to find a safe and effective dose and to see if the drug could help contro…

This study tested an experimental immune therapy called CAR-T cells in Chinese patients with multiple myeloma that had returned or stopped responding to standard treatments. Researchers collected and reprogrammed patients' own immune cells to attack cancer cells, then infused the…

This study tested a special training program designed to help patients recover their sense of taste and smell after finishing chemotherapy for blood cancers like lymphoma or multiple myeloma. The goal was to see if this rehabilitation could improve patients' nutrition, psychologi…

This study aimed to understand how specific markers of bone health change over time in older patients with multiple myeloma who are receiving standard intravenous bisphosphonate treatment. Researchers planned to measure these markers in blood and urine for up to a year to see how…

This study aims to understand why some multiple myeloma patients experience shortness of breath when taking the cancer drug carfilzomib. Researchers will use a special device to measure blood vessel health in 50 patients receiving this treatment. The goal is to identify risk fact…